Literatur
- 1
Neiman J, Haapaniemi H M, Hilborn M.
Neurological complications of drug abuse: pathophysiological mechanisms.
Eur J Neurol.
2000;
7
595-606
- 2
Hill M D, Cooper P W, Perry J R.
Chasing the dragon - neurological toxicity associated with inhalation of heroin vapour:
case report.
CMAJ.
2000;
162
236-238
- 3
Long H, Deore K, Hoffman R S, Nelson L S.
A fatal case of spongiform leukoencephalopathy linked to „chasing the dragon”.
J Toxicol Clin Toxicol.
2003;
41
887-891
- 4
Filley C M, Kleinschmidt-DeMasters B K.
Toxic leukoencephalopathy.
New Engl J Med.
2001;
345
425-432
- 5
Alldredge B K, Lowenstein D H, Simon R P.
Seizures associated with recreational drug abuse.
Neurology.
1989;
39
1037-1039
- 6
Zagoni P G, Albano C.
Psychostimulants and epilepsy.
Epilepsia.
2002;
43 (Suppl 2)
S28-S31
- 7
Ben-Abraham R, Szold O, Rudick V, Weinbroum A A.
„Ecstasy” intoxication: life-threatening manifestations and resuscitative measures
in the intensive care setting.
Eur J Emerg Med.
2003;
10
309-313
- 8
Miro O, Nogue S, Espinosa G. et al .
Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate.
J Toxicol Clin Toxicol.
2002;
40
129-135
- 9
Dyer J E.
γ-Hydroxybutyrate: a health-food product producing coma and seizure-like activity.
Am J Emerg Med.
1991;
9
321-324
- 10
Lowenstein D H, Massa S M, Rowbotham M C. et al .
Acute neurologic and psychiatric complications associated with cocaine abuse.
Am J Med.
1987;
83
841-846
- 11
Andersen S N, Skullerud K.
Hypoxic/brain ischemia damage, especially pallidal lesions, in heroin addicts.
Forensic Sci Int.
1999;
102
51-59
- 12
Fessler R D, Esshaki C M, Stankewitz R C. et al .
The neurovascular complications of cocaine.
Surg Neurol.
1997;
47
339-345
- 13
Aggarwal S K, Williams V, Levine S R. et al .
Cocaine-associated intracranial hemorrhage: absence of vasculitis in 14 cases.
Neurology.
1996;
46
1741-1743
- 14
Buxton N, McConachie N S.
Amphetamine abuse and intracranial haemorrhage.
J R Soc Med.
2000;
93
472-477
- 15
Perez Jr J A, Arsura E L, Strategos S.
Methamphetamine-related stroke: four cases.
J Emerg Med.
1999;
17
469-471
- 16
McEvoy A W, Kitchen N D, Thomas D G.
Intracerebral haemorrhage and drug abuse in young adults.
Br J Neurosurg.
2000;
14
449-454
- 17
Moussouttas M.
Cannabis use and cerebrovascular disease.
Neurologist.
2004;
10
47-53
- 18
Dhuna A, Pascual-Leone A, Belgrade M.
Cocaine-related vascular headaches.
J Neurol Neurosurg Psychiatry.
1991;
54
803-806
- 19
Toth C.
Medications and substances as a cause of headache: a systematic review of the literature.
Clin Neuropharmacol.
2003;
26
122-136
- 20
Poole R, Brabbing C.
Drug-induced psychosis.
Br J Psychiatry.
1996;
168
135-138
- 21
Lejoyeux M, Mourad I, Ades J.
Psychiatric disorders induced by drug dependence other than alcohol.
Encephale.
2000;
26
21-27
- 22
Rogers R D, Robbins T W.
Investigating the neurocognitive deficits associated with chronic drug misuse.
Curr Opin Neurobiol.
2001;
11
250-257
- 23
Nordahl T E, Salo R, Leamon M.
Neuropsychological effects of chronic methamphetamine use on neurotransmitters and
cognition: a review.
J Neuropsychiatry Clin Neurosci.
2003;
15
317-325
- 24
Halpern J H, Pope Jr H G.
Hallucinogen persisting perception disorder: what do we know after 50 years?.
Drug Alcohol Depend.
2003;
69
109-119
- 25
Halpern J H, Pope Jr H G, Sherwood A R. et al .
Residual neuropsychological effects of illicit 3,4-methylendioxymethamphetamine (MDMA)
in individuals with minimal exposure to other drugs.
Drug Alcohol Depend.
2004;
75
135-147
- 26
McCardle K, Luebbers S, Carter J D. et al .
Chronic MDMA (ecstasy) use, cognition and mood.
Psychopharmacology.
2004;
173
434-439
- 27
Vecellio M, Schopper C, Modestin J.
Neuropsychiatric consequences (atypical psychosis and complex-partial seizures) of
ecstasy use: possibile evidence for toxicity-vulnerability predictors and implications
for preventive and clinical care.
J Psychopharmacol.
2003;
17
342-345
- 28
Henquet C, Krabbendam L, Spauwen J. et al .
Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic
symptoms in young people.
BMJ.
2005;
330
11
, doi: 10.1136/bmj.38267.664086.63 (published 1 December 2004)
- 29
Manfredi P L, Gonzales G R, Payne R.
Reversible spastic paraparesis induced by high-dose intravenous metadone.
J Pain.
2001;
2
77-79
- 30
Stamboulis E, Psimaras A, Malliara-loulakaki S.
Brachial and lumbar plexitis as a reaction to heroin.
Drug Alcohol Depend.
1988;
22
205-207
- 31
Bernasconi A, Kuntzer T, Ladbon N. et al .
Complications neurologiques périphériques et médullaires de la toxicomanie intraveineuse
à l'héroine.
Rev Neurol.
1996;
152
688-694
- 32
Pestaner J P, Southall P E.
Sudden death during arrest and phencyclidine intoxication.
Am J Forensic Med Pathol.
2003;
24
119-122
- 33
Green A R, O'Shea E, Colado M I.
A review or the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic
response.
Eur J Pharmacol.
2004;
500
3-13
- 34
Holmes S B, Banerjee A K, Alexander W D.
Hyponatraemia and seizures after ecstasy use.
Postgrad Med J.
1999;
75
32-34
- 35
Hartung T K, Schofield E, Short A I. et al .
Hyponatraemic states following 3,4-methylendioxymethamphetamine (MDMA, „Ecstasy”)
ingestion.
Q J Med.
2002;
95
431-437
- 36
Nath A, Maragos W F, Avison M J. et al .
Acceleration of HIV dementia with methamphetamine and cocaine.
J Neurovirol.
2001;
7
66-71
- 37
Friedman H, Eisenstein T K.
Neurological basis of drug dependence and its effects on the immune system.
J Neuroimmunol.
2004;
147
106-108
- 38
Vallejo R, Leon-Casasola O de, Ramsun B.
Opioid therapy and immunosuppression: a review.
Am J Ther.
2004;
11
354-365
- 39
Connor T J.
Methylendioxymethamphetamine (MDMA, „Ecstasy”): a stressor on the immune system.
Immunology.
2004;
111
357-367
- 40
Bialer P A.
Designer drugs in the general hospital.
Psychiatr Clin North Am.
2002;
25
231-243
- 41
Staack R F, Maurer H H.
Metabolism of designer drugs of abuse.
Curr Drug Metab.
2005;
6
259-274
- 42
Sassenbroeck D K Van, Calle P A, Rousseau F M. et al .
Medical problems related to recreational drug use at nocturnal dance parties.
Eur J Emerg Med.
2003;
10
302-308
- 43
Refstad S.
Paramethoxyamphetamine (PMA) poisoning: a „party drug” with lethal effect.
Acta Anaesthesiol Scand.
2003;
47
1298-1299
- 44
Becker J, Neis P, Röhrich J, Zörntlein S.
A fatal Paroxymethamphetamin intoxication.
Legal Med.
2003;
5 (Suppl)
S138-S141
- 45 Amato L, Davoli M, Minozzi S. et al .Metadone at tapered doses for the management
of opioid withdrawal. Cochrane Database Syst Rev 2005 Jul 20 (3) CD003409
- 46 Ferri M, Davoli M, Amato L. Heroin maintenance for chronic heroin dependents. Cochrane
Database Syst Rev 2005 Apr 18 (2) CD003410
- 47
Amato L, Davoli M, Perucci C A. et al .
An overview of systematic reviews of the effectiveness of opiate maintenance therapies:
available evidence to inform clinical practice and research.
J Subst Abuse Treat.
2005;
28
321-329
- 48
Kosten T R, O'Connor P G.
Management of drug and alcohol withdrawal.
New Engl J Med.
2003;
348
1786-1795
- 49
Umbricht A, Hoover D R, Tucker M J. et al .
Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized
heroin-dependent patients with HIV infection.
Drug Alcohol Depend.
2003;
69
263-272
- 50
Bochud Tornay C, Favrat B, Monnat M. et al .
Ultra-rapid opiate detoxification using deep sedation and prior oral buprenorphine
preparation: long-term results.
Drug Alcohol Depend.
2003;
69
283-288
- 51
Digiusto E, Lintzeris N, Breen C. et al for the NEPOD Research Group .
Short-term outcomes of five heroin detoxification methods in the Australian NEPOD
Project.
Addict Behav.
2005;
30
443-456
- 52
Richmond R, Zwar N.
Review of bupropion for smoking cessation.
Drug Alcohol Rev.
2003;
22
203-222
- 53
Aubin H J, Lebargy F, Berlin I. et al .
Efficacy of bupropion and predictors of successful outcome in a sample of French smokers:
a randomized placebo-controlled trial.
Addiction.
2004;
99
1206-1218
- 54
Fernandez J R, Allison D B.
Rimonabant Sanofi-Synthélabo.
Curr Opin Invest Drugs.
2004;
5
430-435
- 55
Boyd S T, Fremming B A.
Rimonabant - a selective CB1 antagonist.
Ann Pharmacother.
2005;
39
684-690
- 56
Gaal L F Van, Rissanen A M, Scheen A J. et al .
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular
risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Lancet.
2005;
365
1389-1397
- 57
Kantak K M.
Vaccines against drugs of abuse: a viable treatment option?.
Drugs.
2003;
63
341-352
- 58
Martell B A, Mitchell E, Poling J. et al .
Vaccine pharmacotherapy for the treatment of cocaine dependence.
Biol Psychiatry.
2005;
58
158-164
- 59
Ashcroft R E, Franey C.
Further ethical and social issues in using a cocaine vaccine: response to Hall and
Carter.
J Med Ethics.
2004;
30
341-343
Dr. med. Stephan Rüegg
Abt. f. klinische Neurophysiologie · Neurologische Klinik · Universitätsspital
Petersgraben 4
4031 Basel · Schweiz
Email: srueegg@uhbs.ch
